Overcoming Challenges with Cash Management and Reforecasting Clinical Trials

Presented by

James Sacchetta and Jay Trepanier

About this talk

With globalization, large numbers of sites, recent regulatory requirements and an increasing number of CROs and vendors, clinical trials are constantly becoming more complex. Given that clinical trial costs are one of the biggest expense categories for biopharmaceutical companies—the average cost of bringing a drug to market in the US is estimated to be $1.3-1.7 billion—it’s critical that CROs and Sponsors forecast accurately. However, manual processes have made forecasting of clinical trials challenging, leading to difficulties in reforecasting and cash management (and as a result, difficulties in maintaining site satisfaction) as well as hefty fines. Viewers will learn more about: - The consequences of poor forecasting - The difficulties of reforecasting with manual systems - The complexities that make forecasting so challenging - How technology that is purpose-built for clinical trials can help CROs and Sponsors forecast more effectively and accurately

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (45)
Subscribers (2054)
Premier Research is a clinical research company, dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.